Association Between Baseline Hypertension and Longitudinal Functional Status in Obstructive Hypertrophic Cardiomyopathy Treated With Mavacamten

Journal of Cardiac Failure 2026 Open access

Read full text
Authors: Nosheen Reza, Nadim Mahmud, Melissa A. Austin, Ellen Boakye, Estherland Duqueney, Parth Patel, Alejandro de Feria, Nicole Hornsby, Amy Marzolf, Anjali Tiku Owens
DOI: 10.1016/j.cardfail.2025.12.010
Cited by: 1
References: 6

Abstract

Hypertension is common in hypertrophic cardiomyopathy (HCM) yet its impact on patients on long-term mavacamten is unknown. In this single-center observational study of 163 patients with symptomatic obstructive HCM treated with mavacamten for up to 108 weeks, hemodynamic and functional responses stratified by baseline hypertension status (60.7% hypertensive) were compared. Mavacamten produced similar reductions in resting and Valsalva LVOT gradients regardless of hypertension status. However, patients with hypertension had a significantly lower probability of achieving NYHA Class I functional status over time (interaction p=0.01). These findings suggest that hypertension-related factors beyond LVOT obstruction may limit complete functional recovery in obstructive HCM despite effective gradient reduction with mavacamten.

Fields of Study & Subjects

Cardiomyopathy and Myosin Studies Blood Pressure and Hypertension Studies Cardiovascular Function and Risk Factors

Publication details

Journal / source
Journal of Cardiac Failure
Publisher
Elsevier BV
Volume
32
Issue
7
Pages
1277–1280
Publication date
1 February 2026
Language
EN